Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
36 studies found for:    " September 29, 2010":" October 29, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" September 29, 2010":" October 29, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Conditions: Chronic HIV Infection;   HCV Coinfection
Intervention: Drug: Fosamprenavir
2 Completed
Has Results
Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
Condition: HIV
Interventions: Drug: Truvada;   Drug: Raltegravir
3 Completed
Has Results
A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
Condition: HIV-1 Infection
Intervention: Drug: Raltegravir
4 Completed
Has Results
Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients
Condition: HIV Infection
Intervention: Drug: Azithromycin
5 Active, not recruiting Study to Improve Survival Among HIV-Exposed Infants in Botswana
Conditions: HIV Infections;   Neutropenia;   Anemia
Interventions: Drug: cotrimoxazole prophylaxis;   Drug: cotrimoxazole placebo;   Behavioral: exclusive breastfeeding until 6 months of age;   Behavioral: breastfeeding for 12 months
6 Completed Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants
Condition: HIV Infections
Intervention:
7 Completed
Has Results
Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
Conditions: HIV Infections;   Heart Disease
Interventions: Drug: Rosuvastatin 10 mg. daily for 96 weeks;   Drug: Placebo
8 Completed Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
Condition: HIV Infections
Interventions: Biological: Ad35-ENV vaccine;   Biological: Ad26.ENVA.01 vaccine;   Biological: Placebo Control
9 Active, not recruiting Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
Conditions: HIV Infection;   Bone Loss;   Osteopenia;   Osteoporosis
Intervention: Drug: Zoledronic acid
10 Withdrawn Depot Contraception With and Without Lopinavir/Ritonavir
Condition: HIV Infection
Intervention: Drug: DMPA
11 Completed Acceptability Study of Vaginal Films for HIV Prevention
Conditions: HIV Infections;   Anti-Infective Agents
Intervention: Other: No intervention (not applicable)
12 Completed Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.
Conditions: 1- Women;   2- HIV Infection;   3- Followed in West Indies and French Guiana for His Infection;   4- Acceptance of the Use of Nadis® Medical Files
Intervention: Other: Biological Sample collection
13 Unknown  Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)
Conditions: HIV Infection;   Acquired Immunodeficiency Syndrome
Interventions: Drug: Protease Inhibitor;   Drug: Standard-of-care Antiretroviral therapy
14 Completed Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
Conditions: Drug Interactions;   Human Immunodeficiency Virus
Intervention: Drug: Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)
15 Terminated Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 100 mg once daily;   Drug: GSK2248761 200 mg once daily;   Drug: Efavirenz 600 mg once daily
16 Unknown 
Has Results
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: GSK1349572 (dolutegravir);   Drug: raltegravir;   Other: GSK1349572 Placebo;   Other: ABC/3TC;   Other: TDF/FTC;   Other: raltegravir Placebo
17 Unknown  Hydroxychloroquine for Discordant CD4 Responders on Highly Active Antiretroviral Therapy (HAART)
Condition: HIV Infection
Intervention: Drug: Hydroxychloroquine
18 Completed Vaginal Innate Immunity in Normal and HIV-Infected Women
Conditions: HIV;   Pregnancy
Intervention: Other: Vaginal lavage specimen
19 Enrolling by invitation IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents
Conditions: ADHD;   HIV
Intervention:
20 Completed Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
Conditions: HIV;   Hepatitis C;   Liver Fibrosis
Interventions: Drug: Raltegravir;   Drug: Ritonavir-boosted protease inhibitor

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Indicates status has not been verified in more than two years